Aimmune Therapeutics Inc diskutieren
Aimmune Therapeutics Inc
WKN: A14X6J / Name: Aimmune / Aktie / Pharmazeutika / Small Cap /
Überkauft
Gut gelaufen die letzte Zeit heute finaler Anstieg. Mit Kursrückgang muß gerechnet werden.
marge stimmt der Outperform-Einschätzung der institutionellen Analysten zu
marge stimmt am 20.11.2017 der Outperform-Einschätzung der institutionellen Analysten zu.
- Aimmune Therapeutics (NASDAQ:AIMT) initiated with Buy rating and $60 (71% upside) price target by Roth Capital.
Erdnuss-Allergie
„Wir freuen uns auf weitere Fortschritte im Jahr 2018 zu erreichen, vor allem durch die Ergebnisse unserer Zulassungsstudie Phase PALISADE 3 auf der AR101 im Februar teilen“ , sagte Dr. Dilly. „Wir hoffen , dass wir Daten sehen , die stark die letzten Schritte in Richtung auf eine tragfähige Behandlung für Erdnuss - Allergie unterstützen, und wir freuen uns darauf , unser Know - how , um Programme für zusätzliche Allergene zu Anwendung.“
Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.
The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND
stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.
tamam stimmt am 22.02.2018 der Buy-Einschätzung der institutionellen Analysten mit dem Kursziel 55.5$ zu.
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 18.05.2018 der Buy-Einschätzung von tamam mit dem Kursziel 55,5$ zu.
Überschrift: Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.
Up
34$?!
Secteur Recherche biotechnologique et médicale Agenda 02/06 | 12:32 Présentation
Nombre d'employés
: 131 personnes.
Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.
The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND
stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.
Ergebnisse
gut?
Neueste Beiträge
Traumtanz in India Globalization Capital diskutieren